Imunon, INC

Imunon, Inc. announced the retirement of its interim Chief Financial Officer, Jeffrey Church, effective July 1, 2026, and the appointment of Josh Blacher as his successor.

Imunon, Inc. stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the share reserve by 1,000,000 shares.

Imunon, Inc. announced a $10 million financing deal, comprising preferred stock and secured promissory notes, to fund its Phase 3 OVATION 3 study for advanced ovarian cancer.

Imunon, Inc. announced its first quarter 2026 financial results, highlighting progress in its Phase 3 OVATION 3 study for IMNN-001 in ovarian cancer and reporting a net loss of $4.3 million.

Imunon, Inc. has entered into Change in Control Agreements with key executives, providing severance benefits upon termination in specific circumstances related to a change in control.

IMUNON, Inc. reported its 2025 financial results and significant progress in its pivotal Phase 3 study for IMNN-001, showing continued overall survival improvement in advanced ovarian cancer.

Imunon, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.2 million and continued progress in its Phase 3 OVATION 3 ovarian cancer trial.

Imunon, Inc. reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead ovarian cancer immunotherapy into Phase 3 and presenting positive Phase 2 data, despite ongoing going concern doubts.

Imunon reported a reduced net loss and positive clinical data for its lead ovarian cancer immunotherapy, IMNN-001, while addressing significant going concern and Nasdaq listing challenges.

Imunon, Inc. announces its financial results for the first quarter of 2025, highlighting advancements in its IMNN-001 ovarian cancer treatment and IMNN-101 COVID-19 vaccine programs, while also acknowledging substantial doubt about its ability to continue as a going concern.

Imunon, a clinical-stage biotechnology company, announced positive topline results from its Phase II OVATION 2 study of IMNN-001 in advanced ovarian cancer, along with a financial update for the third quarter of 2024.

Imunon reports positive topline results from its Phase II OVATION 2 study for its lead drug candidate, IMNN-001, and provides a financial update for the second quarter of 2024, highlighting a net loss of $9.7 million for the first six months of the year.

Imunon, Inc. announced positive final Phase 2 data for its lead ovarian cancer immunotherapy, IMNN-001, showing significant overall survival benefits, but also disclosed substantial doubt about its ability to continue as a going concern.

Imunon's 10-K filing highlights the company's continued losses, its focus on the IMNN-001 ovarian cancer immunotherapy program, and its next-generation vaccine initiative.

Imunon Inc.'s 10-K filing details the company's financial status, ongoing clinical trials, and advancements in its immunotherapy and vaccine platforms.

Frederick J. Fritz, a Director of Imunon, Inc., received 6,934 shares of common stock on July 31, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,541 shares of common stock on July 31, 2026 for $1.57 per share.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,649 shares of common stock on July 31, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 5,010 shares of common stock on July 31, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 4,603 shares of common stock on July 17, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,150 shares of common stock on July 17, 2026 for $1.78 per share.

Imunon, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, to elect directors, ratify auditors, and vote on executive compensation and stock incentive plan amendments.

IMUNON, INC. is calling for its annual stockholder meeting on July 11, 2025, to vote on critical proposals including a reverse stock split, a significant increase in authorized shares, and the approval of shares underlying recent warrants, all aimed at addressing Nasdaq listing deficiencies and securing future funding.

Imunon, Inc. will hold its annual stockholders meeting virtually on June 12, 2024, to elect directors, ratify the selection of its accounting firm, and conduct an advisory vote on executive compensation.

Imunon, a clinical-stage biotechnology company, is registering shares for resale by existing investors following a private placement, while simultaneously grappling with severe financial challenges, including multiple Nasdaq delisting notices and substantial doubt about its ability to continue as a going concern.

Imunon, Inc. is proceeding with a public offering of common stock and warrants, aiming to raise capital for general corporate purposes, including clinical development.

Imunon, Inc. plans to raise capital through a public offering of up to 15,000,000 shares of common stock and accompanying warrants, aiming to generate approximately $12 million for general corporate purposes.

Imunon, a clinical-stage biotech, aims to raise capital through a public offering of common stock, pre-funded warrants, and common warrants.

Imunon, Inc. has filed an amendment to its Form S-1 registration statement to allow selling stockholders to resell up to 5,000,000 shares of common stock issuable upon the exercise of outstanding warrants.

Imunon, Inc. has filed a registration statement for the resale of up to 5,000,000 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by selling stockholders.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 396,718 shares, representing 9.99% of Imunon, Inc.'s common stock, as of March 31, 2026.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a combined 0.01% beneficial ownership in Imunon, Inc. common stock.

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Imunon, Inc. as of June 30, 2025.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a passive beneficial ownership of 5.5% in Imunon, Inc. common stock.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed a 7.9% beneficial ownership stake in Imunon, Inc., primarily through warrants.